Story
Twist Bioscience Stock Gains After Joining Eli Lilly's AI Drug Discovery Platform
Summary
Shares of Twist Bioscience rose after the company announced it will serve as a preferred data provider for Eli Lilly's AI-powered drug discovery platform, reinforcing its strategic focus on AI applications.
Shares of Twist Bioscience (NASDAQ: TWST) rallied on Wednesday after the synthetic biology company announced it has joined Eli Lilly's collaborative AI-powered drug discovery platform, TuneLab. The partnership underscores the company's strategic pivot toward AI-driven life sciences and was met with positive investor sentiment.
Partnership Details
Under the agreement, Twist will act as a preferred antibody characterization data provider. The company is tasked with generating high-throughput wet lab antibody data using protocols specified by TuneLab.
This data will feed directly into AbLab, Eli Lilly’s proprietary antibody developability prediction model. The integration is designed to help TuneLab’s more than 75 participating companies more rapidly identify and select promising drug candidate molecules.
Market Impact and Strategy
The collaboration reinforces Twist's growing focus on AI applications. According to the company, the quality of its high-throughput data is essential for training reliable AI models. This news pushed the stock up 3.7% in afternoon trading to $143.15, after reaching an intraday high of $148.50.
AdThe rally continues a significant recovery for the stock, which has climbed from a 52-week low of $23.30. The move also builds on existing bullishness following the company's record third-quarter revenue and raised full-year guidance.
Industry Context
The endorsement from Eli Lilly lends significant credibility to Twist's platform, as the TuneLab ecosystem is backed by Lilly's proprietary research data valued at over $1 billion. The partnership highlights a broader sector-wide trend toward using AI to accelerate pharmaceutical development, with companies like Schrödinger also participating in the TuneLab platform.
A supportive market environment, with the NASDAQ Composite advancing 0.7%, provided a further tailwind for growth and biotech stocks during the session.
Read next
More on Stocks
ExxonMobil in Advanced Talks for Venezuela Return, Eyeing Former Orinoco Project
The U.S. oil major is reportedly negotiating a return to the Petromonagas heavy oil project, a significant reversal nearly two decades after its assets were nationalized by the Venezuelan government.
US House Passes Bill Targeting Data Center Power Grid Costs
The U.S. House of Representatives has advanced the Ratepayer Protection Act, the first legislation of its kind aimed at making large power users like data centers bear the costs of new electricity infrastructure.
New Zealand's Q2 GDP Growth Exceeds Forecasts but Remains Tepid at 0.2%
New Zealand's economy grew 0.2% in the second quarter, topping analyst and central bank forecasts, according to official data. However, the pace of expansion remains slow amid persistent economic headwinds and recent interest rate hikes.
Snap Partners With Salesforce, Nvidia to Target Enterprise Market With AR Glasses
Snap Inc. has announced strategic partnerships with Salesforce, Nvidia, and Amazon Web Services to integrate enterprise-grade AI and software tools into its Specs augmented-reality glasses, signaling a major push into the corporate market.